Showing results (161-170 of 175) with videos related to
Sort By:
Pageof 18
American Heart Journal|December 3, 2014
Effect of alirocumab, a monoclonal antibody to PCSK9, on long-term cardiovascular outcomes following acute coronary syndromes: rationale and design of the ODYSSEY outcomes trialGregory G Schwartz, Laurence Bessac, Lisa G Berdan, et al.European Heart Journal|May 7, 2014
Inhibition of delta-protein kinase C by delcasertib as an adjunct to primary percutaneous coronary intervention for acute anterior ST-segment elevation myocardial infarction: results of the PROTECTION AMI Randomized Controlled TrialA Michael Lincoff, Matthew Roe, Philip Aylward, et al.American Heart Journal|November 23, 2022
Rationale and design for the myocardial ischemia and transfusion (MINT) randomized clinical trialJeffrey L Carson, Maria Mori Brooks, Bernard R Chaitman, et al.Journal of the American College of Cardiology|September 4, 2024
ApoA-I Infusions and Burden of Ischemic Events After Acute Myocardial Infarction: Insights From the AEGIS-II TrialC Michael Gibson, Gerald Chi, Danielle Duffy, et al.American Heart Journal|June 17, 2018
Ticagrelor versus clopidogrel after fibrinolytic therapy in patients with ST-elevation myocardial infarction: Rationale and design of the ticagrelor in patients with ST elevation myocardial infarction treated with thrombolysis (TREAT) trialOtavio Berwanger, Jose C Nicolau, Antonio C Carvalho, et al.The New England Journal of Medicine|March 18, 2017
Cardiovascular Efficacy and Safety of Bococizumab in High-Risk PatientsPaul M Ridker, James Revkin, Pierre Amarenco, et al.European Heart Journal|September 2, 2024
Apolipoprotein A-I infusions and cardiovascular outcomes in acute myocardial infarction according to baseline LDL-cholesterol levels: the AEGIS-II trialC Michael Gibson, Danielle Duffy, Maria Cecilia Bahit, et al.The New England Journal of Medicine|July 26, 2011
Apixaban with antiplatelet therapy after acute coronary syndromeJohn H Alexander, Renato D Lopes, Stefan James, et al.JACC. Advances|April 27, 2025
Impact of Apolipoprotein A-I Infusions on Cardiovascular Events Post-MI by Neutrophil-Lymphocyte Ratio and LDL-Cholesterol LevelsSem A O F Rikken, C Michael Gibson, M Cecilia Bahit, et al.JAMA|July 9, 2004
Enoxaparin vs unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndromes managed with an intended early invasive strategy: primary results of the SYNERGY randomized trialJames J Ferguson, Robert M Califf, Elliott M Antman, et al.Pageof 18